Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab

Paul N. Meyer, Kai Fu, Timothy C. Greiner, Lynette M. Smith, Jan Delabie, Randy D. Gascoyne, German Ott, Andreas Rosenwald, Rita Braziel, Elias Campo, Julie M. Vose, Georg Lenz, Louis M. Staudt, Wing C. Chan, Dennis D. Weisenburger

Research output: Contribution to journalArticle

297 Citations (Scopus)

Abstract

Purpose: Patients with diffuse large B-cell lymphoma (DLBCL) can be divided into prognostic groups based on the cell of origin of the tumor as determined by microarray analysis. Various immunohistochemical algorithms have been developed to replicate these microarray results and/or stratify patients according to survival. This study compares some of those algorithms and also proposes some modifications. Patients and Methods: Two-hundred and sixty-two cases of de novo DLBCL treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP-like therapy were examined. Results: The Choi algorithm and Hans algorithm had high concordance with the microarray results. Modifications of the Choi and Hans algorithms for ease of use still retained high concordance with the microarray results. Although the Nyman and Muris algorithms had high concordance with the microarray results, each had a low value for either sensitivity or specificity. The use of LMO2 alone showed the lowest concordance with the microarray results. A new algorithm (Tally) using a combination of antibodies, but without regard to the order of examination, showed the greatest concordance with microarray results. All of the algorithms divided patients into groups with significantly different overall and event-free survivals, but with different hazard ratios. With the exception of the Nyman algorithm, this survival prediction was independent of the International Prognostic Index. Although the Muris algorithm had prognostic significance, it misclassified a large number of cases with activated B-cell type DLBCL. Conclusion: The Tally algorithm showed the best concordance with the microarray data while maintaining prognostic significance and ease of use.

Original languageEnglish (US)
Pages (from-to)200-207
Number of pages8
JournalJournal of Clinical Oncology
Volume29
Issue number2
DOIs
StatePublished - Jan 10 2011
Externally publishedYes

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Cell Survival
Rituximab
Survival
Vincristine
Microarray Analysis
Prednisone
Doxorubicin
Cyclophosphamide
Disease-Free Survival
B-Lymphocytes
Sensitivity and Specificity

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. / Meyer, Paul N.; Fu, Kai; Greiner, Timothy C.; Smith, Lynette M.; Delabie, Jan; Gascoyne, Randy D.; Ott, German; Rosenwald, Andreas; Braziel, Rita; Campo, Elias; Vose, Julie M.; Lenz, Georg; Staudt, Louis M.; Chan, Wing C.; Weisenburger, Dennis D.

In: Journal of Clinical Oncology, Vol. 29, No. 2, 10.01.2011, p. 200-207.

Research output: Contribution to journalArticle

Meyer, PN, Fu, K, Greiner, TC, Smith, LM, Delabie, J, Gascoyne, RD, Ott, G, Rosenwald, A, Braziel, R, Campo, E, Vose, JM, Lenz, G, Staudt, LM, Chan, WC & Weisenburger, DD 2011, 'Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab', Journal of Clinical Oncology, vol. 29, no. 2, pp. 200-207. https://doi.org/10.1200/JCO.2010.30.0368
Meyer, Paul N. ; Fu, Kai ; Greiner, Timothy C. ; Smith, Lynette M. ; Delabie, Jan ; Gascoyne, Randy D. ; Ott, German ; Rosenwald, Andreas ; Braziel, Rita ; Campo, Elias ; Vose, Julie M. ; Lenz, Georg ; Staudt, Louis M. ; Chan, Wing C. ; Weisenburger, Dennis D. / Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. In: Journal of Clinical Oncology. 2011 ; Vol. 29, No. 2. pp. 200-207.
@article{e39e65cc97174229b93d4b809a4cb57c,
title = "Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab",
abstract = "Purpose: Patients with diffuse large B-cell lymphoma (DLBCL) can be divided into prognostic groups based on the cell of origin of the tumor as determined by microarray analysis. Various immunohistochemical algorithms have been developed to replicate these microarray results and/or stratify patients according to survival. This study compares some of those algorithms and also proposes some modifications. Patients and Methods: Two-hundred and sixty-two cases of de novo DLBCL treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP-like therapy were examined. Results: The Choi algorithm and Hans algorithm had high concordance with the microarray results. Modifications of the Choi and Hans algorithms for ease of use still retained high concordance with the microarray results. Although the Nyman and Muris algorithms had high concordance with the microarray results, each had a low value for either sensitivity or specificity. The use of LMO2 alone showed the lowest concordance with the microarray results. A new algorithm (Tally) using a combination of antibodies, but without regard to the order of examination, showed the greatest concordance with microarray results. All of the algorithms divided patients into groups with significantly different overall and event-free survivals, but with different hazard ratios. With the exception of the Nyman algorithm, this survival prediction was independent of the International Prognostic Index. Although the Muris algorithm had prognostic significance, it misclassified a large number of cases with activated B-cell type DLBCL. Conclusion: The Tally algorithm showed the best concordance with the microarray data while maintaining prognostic significance and ease of use.",
author = "Meyer, {Paul N.} and Kai Fu and Greiner, {Timothy C.} and Smith, {Lynette M.} and Jan Delabie and Gascoyne, {Randy D.} and German Ott and Andreas Rosenwald and Rita Braziel and Elias Campo and Vose, {Julie M.} and Georg Lenz and Staudt, {Louis M.} and Chan, {Wing C.} and Weisenburger, {Dennis D.}",
year = "2011",
month = "1",
day = "10",
doi = "10.1200/JCO.2010.30.0368",
language = "English (US)",
volume = "29",
pages = "200--207",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "2",

}

TY - JOUR

T1 - Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab

AU - Meyer, Paul N.

AU - Fu, Kai

AU - Greiner, Timothy C.

AU - Smith, Lynette M.

AU - Delabie, Jan

AU - Gascoyne, Randy D.

AU - Ott, German

AU - Rosenwald, Andreas

AU - Braziel, Rita

AU - Campo, Elias

AU - Vose, Julie M.

AU - Lenz, Georg

AU - Staudt, Louis M.

AU - Chan, Wing C.

AU - Weisenburger, Dennis D.

PY - 2011/1/10

Y1 - 2011/1/10

N2 - Purpose: Patients with diffuse large B-cell lymphoma (DLBCL) can be divided into prognostic groups based on the cell of origin of the tumor as determined by microarray analysis. Various immunohistochemical algorithms have been developed to replicate these microarray results and/or stratify patients according to survival. This study compares some of those algorithms and also proposes some modifications. Patients and Methods: Two-hundred and sixty-two cases of de novo DLBCL treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP-like therapy were examined. Results: The Choi algorithm and Hans algorithm had high concordance with the microarray results. Modifications of the Choi and Hans algorithms for ease of use still retained high concordance with the microarray results. Although the Nyman and Muris algorithms had high concordance with the microarray results, each had a low value for either sensitivity or specificity. The use of LMO2 alone showed the lowest concordance with the microarray results. A new algorithm (Tally) using a combination of antibodies, but without regard to the order of examination, showed the greatest concordance with microarray results. All of the algorithms divided patients into groups with significantly different overall and event-free survivals, but with different hazard ratios. With the exception of the Nyman algorithm, this survival prediction was independent of the International Prognostic Index. Although the Muris algorithm had prognostic significance, it misclassified a large number of cases with activated B-cell type DLBCL. Conclusion: The Tally algorithm showed the best concordance with the microarray data while maintaining prognostic significance and ease of use.

AB - Purpose: Patients with diffuse large B-cell lymphoma (DLBCL) can be divided into prognostic groups based on the cell of origin of the tumor as determined by microarray analysis. Various immunohistochemical algorithms have been developed to replicate these microarray results and/or stratify patients according to survival. This study compares some of those algorithms and also proposes some modifications. Patients and Methods: Two-hundred and sixty-two cases of de novo DLBCL treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP-like therapy were examined. Results: The Choi algorithm and Hans algorithm had high concordance with the microarray results. Modifications of the Choi and Hans algorithms for ease of use still retained high concordance with the microarray results. Although the Nyman and Muris algorithms had high concordance with the microarray results, each had a low value for either sensitivity or specificity. The use of LMO2 alone showed the lowest concordance with the microarray results. A new algorithm (Tally) using a combination of antibodies, but without regard to the order of examination, showed the greatest concordance with microarray results. All of the algorithms divided patients into groups with significantly different overall and event-free survivals, but with different hazard ratios. With the exception of the Nyman algorithm, this survival prediction was independent of the International Prognostic Index. Although the Muris algorithm had prognostic significance, it misclassified a large number of cases with activated B-cell type DLBCL. Conclusion: The Tally algorithm showed the best concordance with the microarray data while maintaining prognostic significance and ease of use.

UR - http://www.scopus.com/inward/record.url?scp=79951990286&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951990286&partnerID=8YFLogxK

U2 - 10.1200/JCO.2010.30.0368

DO - 10.1200/JCO.2010.30.0368

M3 - Article

VL - 29

SP - 200

EP - 207

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 2

ER -